TMED3 and prostate carcinoma: The IHC results showed that TMED3-downregulated mice exhibited a lower percentage of Ki67+ tumor cells than did mice in the shCtrl group, which implied that TMED3 was associated with the modulatory process of apoptosis in prostate cancer (Fig. 5E).